Bictegravir Co-Formulation Maintained High Levels of Virologic Suppression in HIV

Share this content:
Serious adverse events were similar between the two regimens.
Serious adverse events were similar between the two regimens.
This article is part of Infectious Disease Advisor's coverage of IDWeek 2017™, taking place in San Diego, CA. Our on-site staff will be reporting on the latest breaking research and clinical advances in infectious diseases. Check back regularly for highlights from IDWeek 2017.

SAN DIEGO – Among HIV-infected adults whose disease was virologically suppressed on a boosted protease inhibitor regimen, switching to bictegravir coformulated with emtricitabine/tenofovir alafenamide was safe and maintained high levels of virologic suppression, according to research presented at IDWeek 2017.

In this phase 3 study, researchers enrolled 577 adults (17% women, 26% black, median age 48 years) with HIV who had virologic suppression to receive bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg (n = 290) or continue their boosted protease inhibitor regimens (n = 287). At baseline, all patients were receiving a boosted protease regimen. Most were receiving emtricitabine/tenofovir disoproxil fumarate. The primary end point of the study was the proportion of patients who continued to have virologic suppression at 48 weeks (HIV-1 RNA ≥50 copies/mL). 

At 48 weeks, the two groups had similar rates of patients whose disease was not virologically suppressed (1.7% vs 1.7%; P =1.0), which met the predefined criteria for noninferiority. Additionally, 92.1% of patients in the bictegravir group had HIV-1 RNA <50 copies/mL compared with 88.9% in the group that did not switch.

No participants in the bictegravir group developed resistance, whereas a drug-resistant mutation occurred in one participant who was receiving darunavir plus abacavir/lamivudine.

Serious adverse events were similar between the 2 regimens, with grade 3 or 4 adverse events occurring in 4% of patients in the bictegravir group and 6% of patients in the boosted protease inhibitor group. No participants in the bictegravir group discontinued because of renal complications or tubulopathy.

 

The study authors concluded that “adults switching to [bictegravir/emtricitabine/tenofovir alafenamide] from a boosted [protease inhibitor] maintained high rates of virologic suppression without resistance. [Bictegravir/emtricitabine/tenofovir alafenamide] was safe and well tolerated.”

Disclosures

With the exception of Godson Oguchi, MD, and Ellen Koenig, MD, the remaining authors have either received a consulting fee or are employed by Gilead. A full listing of disclosures can be viewed here.

Visit Infectious Disease Advisor's conference section for continuous coverage live from IDWeek 2017.

Reference

Daar E, DeJesus E, Ruane P, et al. Phase 3 randomized, controlled trial of switching to fixed-dose bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) from boosted protease inhibitor-based regimens in virologically suppressed adults: week 48 results. Presented at: IDWeek 2017; October 4-8, 2017; San Diego, CA. Oral Abstract LB-4.

You must be a registered member of Infectious Disease Advisor to post a comment.

Upcoming Meetings

Sign Up for Free e-newsletters